Biological Therapeutics for Infection-Relating Disorders or Conditions

Abstract

The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, scrum or plasma, specific antibodies to viral pathogens.

Claims

1-36. (canceled)

37. A substance or product which interrupts the binding of a harmful antibody to a host cell or tissue, wherein the substance or the product is: a) serum or plasma, wherein the serum or plasma is pooled from multiple individuals; b) an immunoglobulin or an antibody different from the harmful antibody, wherein the immunoglobulin or antibody is formulated as lyophilized, an injectable, or an infusion; or c) a pathogen-deriving product, a host-deriving product, or a saccharide, wherein the product or saccharide is formulated as lyophilized, an injectable, or an infusion; wherein the harmful antibody is induced by a pathogen, a vaccine or a passively introduced therapeutic antibody; and wherein the harmful antibody binds to a host cell or tissue and induces infection-relating disorders including autoimmune diseases, infection-relating inflammation, serious adverse reactions of vaccines or therapeutic antibodies, infection-relating tumors, infection-relating allergies, and other infection-relating disorders.

38. The substance or product of claim 37, wherein the pathogen comprises at least one of a virus, a bacteria, a parasite, a fungi, a viroid, or a prion.

39. The substance or product of claim 37, wherein the vaccine comprises an influenza vaccine.

40. The substance or product of claim 37, wherein the serum or plasma is formulated as lyophilized, an injectable, or an infusion.

41. A vaccine comprising a first pathogen which induces antibodies capable of protecting an infection caused by a second pathogen.

42. The vaccine of claim 41, wherein the first pathogen comprises at least one of a hepatitis A virus (HAV), a hepatitis B virus (HBV), a respiratory syncytial virus (RSV), or a rotavirus.

43. The vaccine of claim 41, wherein the second pathogen comprises an influenza virus.

44. A method of using a vaccine made of a first pathogen for preventing and treating diseases and conditions relating to an infection caused by a second pathogen, wherein the vaccine is capable of inducing antibodies capable of preventing an infection caused by a second pathogen; and wherein the vaccine is capable of inducing antibodies capable of interrupting, competing or neutralizing harmful antibodies induced by the second pathogen.

45. The method of claim 44, wherein the second pathogen comprises an influenza virus.

Description

BRIEF DESCRIPTION OF THE DRAWING

[0179] FIG. 1 is a graphical representation of histology changes of lungs from the mouse pups delivered to the dams treated with human serum of healthy individuals (A) or the anti-09H1N1 influenza viruus serum (B). This data showed that antibodies induced by the 09H1N1 influenza vims are harmful to fetuses and newborns since it caused later fetal death (still birth) and neonatal death.

ADDITIONAL EMBODIMENTS

[0180] Another embodiment of the present invention discloses therapeutic products comprising a vaccine or an inactivated pathogen for the treatment of a severe infection caused by antibodies induced during an infection; wherein the therapeutic vaccines or inactivated pathogens neutralize harmful antibodies induced during the infection.

[0181] Another embodiment of the present invention discloses a method of administrating a therapeutic vaccine or an inactivated pathogen to a patient to prevent or treat the disorders or conditions caused by the antibodies against the vaccine or the pathogen; wherein the antibodies are induced during an infection; the therapeutic vaccines or inactivated pathogens neutralize harmful antibodies induced during the infection.

[0182] Other embodiments besides the above may be articulated as well. The terms and expressions therefore serve only to describe the disclosure by example only and not to limit the disclosure. It is expected that others will perceive differences, which while differing from the foregoing, do not depart from the spirit and scope of the disclosure herein described and claimed. All patents, patent publications, and other references cited herein are incorporated herein by reference in their entirety.